Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan

This study included 51 patients with muscle-specific kinase antibody-positive myasthenia gravis (MuSK-MG) from a Japanese multicenter survey to examine clinical features and outcomes. Median onset age was 37 years and female predominance was observed. All patients developed generalized symptoms and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuroimmunology 2023-12, Vol.385, p.578241, Article 578241
Hauptverfasser: Yasuda, Manato, Uzawa, Akiyuki, Kuwabara, Satoshi, Suzuki, Shigeaki, Akamine, Hiroyuki, Onishi, Yosuke, Ozawa, Yukiko, Kawaguchi, Naoki, Kubota, Tomoya, Takahashi, Masanori P, Suzuki, Yasushi, Watanabe, Genya, Kimura, Takashi, Sugimoto, Takamichi, Samukawa, Makoto, Minami, Naoya, Masuda, Masayuki, Konno, Shingo, Nagane, Yuriko, Utsugisawa, Kimiaki
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study included 51 patients with muscle-specific kinase antibody-positive myasthenia gravis (MuSK-MG) from a Japanese multicenter survey to examine clinical features and outcomes. Median onset age was 37 years and female predominance was observed. All patients developed generalized symptoms and almost all (50/51) patients had bulbar symptoms. About half of the patients met the criteria for refractory MG. The refractory group had a lower age of onset, higher severity scores, and higher maximum daily doses of oral prednisolone compared to the nonrefractory group. The outcomes for MuSK-MG patients in Japan are not favorable, indicating the need for more aggressive treatment.
ISSN:0165-5728
1872-8421
1872-8421
DOI:10.1016/j.jneuroim.2023.578241